Therapy
|
OctagamŽ |
NDC Number
|
Lot Number
|
Size
|
Packaging
|
Expiration Date
|
67467 0843 03 |
A002B8431 |
5 GM |
Vial |
01-01-2012 |
67467 0843 03 |
A008C8431 |
5 GM |
Vial |
02-28-2012 |
67467 0843 04 |
A009A8431 |
10 GM |
Vial |
03-03-2012 |
67467 0843 04 |
A009C8431 |
10 GM |
Vial |
03-04-2012 |
67467 0843 04 |
A010A8431 |
10 GM |
Vial |
03-10-2012 |
67467 0843 04 |
A010C8431 |
10 GM |
Vial |
03-11-2012 |
67467 0843 04 |
A011B8431 |
10 GM |
Vial |
03-17-2012 |
67467 0843 04 |
A011C8431 |
10 GM |
Vial |
03-18-2012 |
67467 0843 04 |
A012B8431 |
10 GM |
Vial |
03-24-2012 |
67467 0843 04 |
A012C8431 |
10 GM |
Vial |
03-25-2012 |
67467 0843 04 |
A012D8431 |
10 GM |
Vial |
03-25-2012 |
67467 0843 04 |
A012E8431 |
10 GM |
Vial |
03-26-2012 |
67467 0843 03 |
A013A8431 |
5 GM |
Vial |
03-31-2012 |
67467 0843 03 |
A013B8431 |
5 GM |
Vial |
03-31-2012 |
67467 0843 04 |
A013C8431 |
10 GM |
Vial |
04-01-2012 |
67467 0843 03 |
A014A8431 |
5 GM |
Vial |
04-07-2012 |
67467 0843 04 |
A014B8431 |
10 GM |
Vial |
04-07-2012 |
67467 0843 04 |
A014C8431 |
10 GM |
Vial |
04-08-2012 |
67467 0843 04 |
A014D8431 |
10 GM |
Vial |
04-08-2012 |
67467 0843 04 |
A015A8431 |
10 GM |
Vial |
04-14-2012 |
67467 0843 04 |
A015B8431 |
10 GM |
Vial |
04-15-2012 |
67467 0843 04 |
A015C8431 |
10 GM |
Vial |
04-15-2012 |
67467 0843 04 |
A016B8431 |
10 GM |
Vial |
04-22-2012 |
67467 0843 04 |
A016C8431 |
10 GM |
Vial |
04-23-2012 |
67467 0843 04 |
A016D8431 |
10 GM |
Vial |
04-22-2012 |
68209 0843 04 |
C011C8431 |
10 GM |
Vial |
03-18-2012 |
68209 0843 04 |
C013C8431 |
10 GM |
Vial |
04-01-2012 |
68209 0843 04 |
C025A8431 |
10 GM |
Vial |
06-23-2012 |
67467 0843 04 |
A004A8431 |
10 GM |
Vial |
01-27-2012 |
67467 0843 04 |
A004B8431 |
10 GM |
Vial |
01-28-2012 |
67467 0843 04 |
A008B8431 |
10 GM |
Vial |
02-25-2012 |
|
Reason
|
This voluntary withdrawal is being conducted as a precautionary measure. In the interest of patient safety, Octapharma USA Inc. has initiated a voluntary market withdrawal of selected lots of octagamŽ [immune globulin intravenous (human)] 5% Liquid Preparation] as a result of an increased number of reported thromboembolic events, some of which were serious. |
Action
|
1) Please check all product labels against the list of affected lot numbers. 2) Do not take this product. Return any product from the withdrawn lots to the point of purchase or to your healthcare provider. 3) Contact your physician if you have medical questions. |
Other Information
|
If you need assistance, please call Octapharma USA Medical Affairs Department at 360 990 4318. |